In 2009, the Cytopathology Education and Technology Consortium issued a statement on
human papillomavirus (HPV) DNA test utilization that was published in multiple journals. 1 …

Testing for carcinogenic or high-risk human papillomavirus (HPV) DNA has proven utility in
cervical cancer screening and in many aspects of clinical management for cervical cancer …

Testing for carcinogenic or high-risk human papillo-mavirus (HPV) DNA has proven utility in
cervical cancer screening and in many aspects of clinical management for cervical cancer …

In September 2017, the United States Preventive Services Task Force put forth updated draft
guidelines for cervical cancer screening in the United States, which were then open to public …

Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug
Administration for use as an adjunct to cytology for cervical cancer screening. To help …

In 2001, scientists and clinicians in gynecology and pathology gathered with the common
goals of standardizing and improving the quality of patient care for women with abnormal …

Introduction Cervical screening has undergone significant changes in recent years, with
molecular human papillomavirus (HPV) testing for HPV 16 and 18 at the forefront of clinical …

OBJECTIVE: We assessed clinician knowledge and practices since the marketing of tests for
sexually transmitted human papillomavirus (HPV) and the release of HPV testing guidelines …

Blatt et al1 have presented data regarding the correlations of routine high-risk human
papillomavirus (HPV) and Papanicolaou (Pap)“cotesting” results with biopsy diagnosis in …

The article by Albrow et al in this issue describes the early cervical screening program in
England as being “disorganized,” but goes on to describe significant improvements over 20 …